{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:11:35Z","timestamp":1772752295595,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000924","name":"MS Research","doi-asserted-by":"publisher","award":["16311"],"award-info":[{"award-number":["16311"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.msard.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T02:36:36Z","timestamp":1543804596000},"page":"31-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis"],"prefix":"10.1016","volume":"28","author":[{"given":"Blake","family":"Giarola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Massey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.12.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.msard.2018.12.004_bib0002","doi-asserted-by":"crossref","first-page":"e6181","DOI":"10.1097\/MD.0000000000006181","article-title":"Limbic encephalitis associated with anti-NH2-terminal of alpha-enolase antibodies: a clinical subtype of Hashimoto encephalopathy","volume":"96","author":"Kishitani","year":"2017","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.msard.2018.12.004_bib0003","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000363178","article-title":"Steroid-responsive Epilepsia Partialis continua with anti-thyroid antibodies: a spectrum of Hashimoto's Encephalopathy?","volume":"6","author":"Masuda","year":"2014","journal-title":"Case Rep. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2018.12.004_bib0004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40478-016-0352-1","article-title":"Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis","volume":"4","author":"Metz","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"2","key":"10.1016\/j.msard.2018.12.004_bib0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:42:34Z","timestamp":1761900154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":5,"alternative-id":["S2211034818305327"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.004","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}